公开(公告)号：WO1995004829A1

公开(公告)日：1995-02-16

申请号：PCT/US1994008809

申请日：1994-08-05

Applicant: SHISEIDO CO., LTD. ,  THE GENERAL HOSPITAL CORPORATION

Inventor： SHISEIDO CO., LTD. ,  THE GENERAL HOSPITAL CORPORATION ,  TAJIMA, Masahiro ,  OHNUMA, Manami ,  LERNER, Ethan, L.

IPC: C12N15/62

CPC classification number: C07K14/43577 ,  A61K38/00 ,  C07K2319/00

Abstract: A modified maxadilan protein exhibits higher biological activity than native maxadilan from the sand fly Lutzomyia longipalpis. A modified maxadilan fusion protein contains a thrombin cleavage site. This enables the production of the modified maxadilan as a fusion protein and recovery of the modified maxadilan after digestion with thrombin. The modified maxadilan is a potent vasodilator.

Abstract translation: 改良的maxadilan蛋白显示比来自沙蝇Lutzomyia longipalpis的天然maxadilan更高的生物活性。 修饰的maxadilan融合蛋白含有凝血酶切割位点。 这使得生产改性的maxadilan作为融合蛋白，并在凝血酶消化后回收改性的maxadilan。 改性的maxadilan是一种有效的血管扩张剂。

公开(公告)号：WO1997040388A1

公开(公告)日：1997-10-30

申请号：PCT/JP1997001394

申请日：1997-04-23

Applicant: SHISEIDO COMPANY, LTD. ,  THE GENERAL HOSPITAL CORPORATION

Inventor： SHISEIDO COMPANY, LTD. ,  THE GENERAL HOSPITAL CORPORATION ,  MORO, Osamu ,  WAKITA, Kawori ,  HYOCHI, Manami ,  LERNER, Ethan, A. ,  TAJIMA, Masahiro

IPC: G01N33/68

CPC classification number: G01N33/6842 ,  A61K38/00 ,  C07K14/47 ,  C07K14/57563 ,  G01N33/68

Abstract: This specification relates to use of peptides having a specific affinity to subtype 1 of PACAP (pituitary adenylate cyclase activating polypeptide) receptors, particularly MAX (67 amino acids), NSP (61 amino acids) and M 65 (46 amino acids). MAX and NSP act as agonists to PACAP type 1 receptors, and M 65 acts as an antagonist to PACAP type 1 receptors.

Abstract translation: 本说明书涉及对PACAP（垂体腺苷酸环化酶活化多肽）受体，特别是MAX（67个氨基酸）NSP（61个氨基酸）和M65（46个氨基酸）亚型具有特异性亲和力的肽的用途。 MAX和NSP作为PACAP 1型受体的激动剂，M65作为PACAP 1型受体的拮抗剂。